0001610717-24-000236.txt : 20240509
0001610717-24-000236.hdr.sgml : 20240509
20240509160351
ACCESSION NUMBER: 0001610717-24-000236
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240506
FILED AS OF DATE: 20240509
DATE AS OF CHANGE: 20240509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Felsch Robert Ora
CENTRAL INDEX KEY: 0001917819
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36485
FILM NUMBER: 24930357
MAIL ADDRESS:
STREET 1: C/O ARDELYX, INC.
STREET 2: 34175 ARDENWOOD BLVD.
CITY: FREMONT
STATE: CA
ZIP: 94555
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARDELYX, INC.
CENTRAL INDEX KEY: 0001437402
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 34175 ARDENWOOD BLVD.
CITY: FREMONT
STATE: CA
ZIP: 94555
BUSINESS PHONE: 510-745-7047
MAIL ADDRESS:
STREET 1: 34175 ARDENWOOD BLVD.
CITY: FREMONT
STATE: CA
ZIP: 94555
FORMER COMPANY:
FORMER CONFORMED NAME: NTERYX INC
DATE OF NAME CHANGE: 20080611
4
1
form4.xml
X0508
4
2024-05-06
0001437402
ARDELYX, INC.
ARDX
0001917819
Felsch Robert Ora
C/O ARDELYX, INC.
400 FIFTH AVENUE, SUITE 210
WALTHAM
MA
02451
true
See Remarks
false
Common Stock
2024-05-06
4
M
0
79101
0.84
A
263935
D
Common Stock
2024-05-06
4
M
0
40000
2.75
A
303935
D
Common Stock
2024-05-06
4
S
0
152988
8.8079
D
150947
D
Common Stock
2024-05-06
4
S
0
55000
8.8
D
95947
D
Stock Option (Right to Buy)
0.84
2024-05-06
4
M
0
79101
0
D
2032-02-01
Common Stock
79101
61525
D
Stock Option (Right to Buy)
2.75
2024-05-06
4
M
0
40000
0
D
2033-01-05
Common Stock
40000
80000
D
This transaction was executed in multiple trades in prices ranging from $8.63 to $9.01, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Twenty Five Percent (25%) of the shares subject to the option vest on February 1, 2023 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
SVP Finance and Chief Accounting Officer
/s/ Elizabeth Grammer, Attorney-in-Fact for Robert Ora Felsch
2024-05-09